SMAD4 and neoplasm: In pancreatic cancer specifically, patient-derived models such as organoids and xenografts have allowed for a more nuanced understanding of the tumor’s heterogeneity, offering insights into how genetic mutations, such as those in the Smad4 gene, contribute to tumor growth and resistance to therapy.